The practice of preparing patients about to undergo electroshock treatment with atropine has been re-examined in the light of the great variety of practices which prevail both in terms of dose, route of administration and timing of the drug, as reported in the literature. By using patients as their own controls in the course of a series of treatments, it was determined that there are no appreciable differences between intravenous atropine given in different doses at different times and no atropine at all. Since no evidence wasfound that atropine contributes to cardiovascular stability or to consistent drying of secretions, and since its omission was not accompanied by untoward effects, it is suggested that the agent is not needed nor even necessarily desirable as a premedicant in electroshock therapy.
atropine. 3 Following the publication of this work, it became routine practice in our hospital to precede every electroshock treatment by a relatively large dose of intravenous atropine (1.0 mg).
Given the rather tenuous evidence on which our own practice was based, we reinvestigated the need for atropine.
MATERIALS AND METHODS Thirty-nine patients were studied who between them accounted for 297 electroshock treatments. Each patient served as his or her own control since all had at least five treatments. The study had been submitted to and approved by the "President's Advisory Committee for Human Experimentation". All patients were fasting, and all treatments were given in the morning. The group comprised 10 men and 29 women and ages ranged from 18 to 75 years. All patients receiving electroshock treatment during the period of the study were automatically included except for one who had frequent ventricular premature beats, and another who had recently been in congestive heart failure. Concomitant psychotropic drugs differed from patient to patient, but they remained constant for anyone particular individual, so that the influence of this variable, spread over the entire group, can be ignored. Methohexitone 1.0 per cent was used in all patients for induction and suxamethonium for relaxation. In most instances the dose of methohexitone was 60 mg and that of suxamethonium 50 mg. If it became necessary to change the dose of either agent at a subsequent treatment, the larger number of treatments with a particular dosage schedule only were included in the study. Five different modes of preparation with atropine were studied yielding five groups of patients: 1. Atropine intravenously (IV) 1.0 mg two minutes before induction. 2. Atropine IV 0.5 mg two minutes before induction. 3. Atropine IV 1.0 mg ten seconds before induction. 4. Atropine IV 0.5 mg ten seconds before induction. 5. No atropine.
The sequence of these five groups was at random for each patient. Oxygen was administered by face mask before the shock, resumed immediately thereafter and continued until adequate spontaneous respiration had become re-established. Throughout the anaesthesia lead 2 of the electrocardiogram was monitored and recorded, as well as the pulse by means of a plethysmograph attached to one big toe. Thus, while the electrocardiogram was = I 1 .... obliterated during the shock, the presence of cardiac activity could be ascertained from the plethysmogram. On cessation of the current the electrocardiogram reappeared instantaneously ( Figure 1 ). The equipment used was a Siemens 302 Amplifier and 803 Recorder. Although both electrocardiogram and pulse were continuously recorded, there were six distinct stages of observation in the course of each treatment at which they were specifically noted. These were: A. before the start of treatment; B. immediately after the injection of atropine in those instances in which the drug was used; C. immediately before the administration of the shock; D. during the postshock convulsion; E. during post-shock period, and F. at recovery, that is when spontaneous respiration had returned. Means were calculated of pulse rates at each of the six stages of observation for each of the five premedication groups. Statistical evaluations were done between each of the five groups at each stage of observation. Analyses were done by one-and two-way analysis of variance and by the multiple range test of Newman-Keuls. These several tests were necessary because the total number of treatments varied from patient to patient.
RESULTS
Although the base-line pulse rates varied from patient to patient and for the same patient at the start of each treatment, the means for each group are remarkably close ( Figure 2 ). No significant change resulted immediately from the administration of atropine, but by the time the shock was administered the pulse rate had risen significantly in all five groups, even in the one in which no atropine had been given at all. A further highly significant rise occurred in all five groups to maximum tachycardia during convulsion with only slight falls at the end of convulsions. From thereon the pulse rate did not change until recovery from paralysis and recovery of consciousness. At all six points of observation differences between the five groups were non-significant (p < 0.05). Omission of atropine or use of only 0.5 mg immediately before the shock did not seem to influence the incidence of cardiac irregularities. With one exception, only a rare ventricular premature beat was noted during the entire course of the experiment, and these were not limited to the group which had had no atropine or was given it immediately before the shock.
Anaesthesia and Intensive Care, Vol. VUl, No. 4, November, 1980 Bradycardia, defined as a pulse rate of 60 beats per minute or less, was seen in only two instances, both times in the same patient. The pulse rate in each case had been 60 per minute before the shock, despite preparation with atropine 0.5 mg in one instance and "no atropine" in the other. In this latter case, the bradycardia persisted into the post-shock period, but the rate rose to 72 with resumption of spontaneous respiration. In reviewing the figures, it is impressive that those patients who had a slow pulse pre-treatment also had a slow pulse following the shock and that a fast preshock pulse rate was invariably associated with tachycardia at the conclusion of treatment, and that all this was uninfluenced by the medication which had preceded it.
The degree of salivation was judged on clinical grounds. No sialorrhoea was encountered, sufficient to interfere with a free airway. The remaining instances of salivation were classified as "slight", "moderate", or "marked" and are listed in Table 1 . Eight patients of 39 (20.5 per cent) had some degree of salivation at one or more treatments. Thirteen instances of salivation in all were observed of a total of 297 treatments, representing an incidence of 4.4 per cent. The striking fact is its inconsistency. One patient exhibited salivation only once in 37 treatments, many of them without atropine preparation, as was the one under consideration. Of the other five occasions when "marked" salivation was recorded, three occurred after atropine 1.0 mg two minutes before induction, whereas in three instances in which atropine had been omitted only "slight" salivation was recorded. This does not count, of course, the over 50 treatments without atropine preparation when no salivation at all occurred.
DISCUSSION
The mortality associated with electroshock therapy is exceedingly low. It has been given variously as 1: 1O,()()(t or 5 :70,000 treatments 5 and as 0.0036 per cent,6 while Kalinowsky and sometimes as late as 20 minutes after completion of the procedure. 9 "o", No information can be gleaned from these reports of the adequacy of pre-and post-shock oxygenation, nor of the state of respiration in the immediate post-shock period. All that is known is that some fatalities have been shown as having been due to myocardial infarction. ' 2 It has been postulated that this may have been the result of increased cardiac work during the shock with the damage occurring perhaps shortly after, rather than during the convulsion. 13 Pretreatment anxiety may have been responsible for some of the other deaths.'4 Indeed, even one of our patients exhibited runs of ventricular premature beats at the first treatment when he was struggling and had to be forcibly restrained. Causes of late deaths in the literature have included fat embolism, a ruptured duodenum, haemorrhage into the internal capsule and into the thyroid, as well as multiple fractures with pulmonary oedema. '5 These can be attributed only indirectly to the treatment, but one is left to wonder how adequate the shock modification can have been in these individuals, when lesions of such severity could ensue. It has been pointed out by some that there is danger in the combination of electroshock treatment with tricyclic antidepressants on account of their inherent cardiotoxicity.'4,'6 Yet they are important in the overall treatment of these patients, if early relapse is to be prevented. It is doubtful whether any of these causes of death can be influenced by atropine in one way or the other. There is a wide variety of attitudes towards the preparation with atropine. There are those who give no atropine, either because it is not required in their estimation, or because it is considered inadvisable '7 while others consider it essential. 's There is some evidence from animal studies that the reduction of parasympathetic inhibition by the anticholinergics could even increase mortality because of the adrenergically mediated reaction to the electroconvulsion. '9 On the other hand, the adrenergic response is frequently followed by bradycardia after the postshock convulsion has subsided and atropine could be useful in treating this situation. There are those who recommend complete atropinization with 1.5 to 2 mg intravenouslY,2o,21,22 while Rich and Pitts 23 have given anything between 0.65 and 2.5 mg subcutaneously without having encountered a life-threatening vagally induced arrhythmia. Administration of atropine 0.4 to 0.65 mg even subcutaneously is quite common 23 ,24 while McCleave and Blakemore 25 could report a series of 3,500 administrations to 425 patients in which atropine 0.6 mg was given either before induction, with the induction agent or with the relaxant. Despite this, 11 of their postinfarction patients failed to show alterations in cardiac rhythm. Such wide variance in Anaesthesia and Intensive Care, Vol. VUf. No. 4, November, 1980 technique must put in serious doubt the necessity for the use of atropine. Yet arrhythmias do occur, more in the experiences of some than of others. Very few conclusions can be drawn why this should be so, since information is scanty on such factors as oxygenation and ventilation, but Pitts 26 and Woodruff and associates 27 point out that fewer electrocardiographic abnormalities are seen when methohexitone is used as the anaesthetic than thiopentone, following premedication with atropine 0.6 to 1 mg 30 to 60 minutes preshock. This may be significant in the light of our own experiences which shed serious doubt on the necessity for the use of atropine, at least in patients with a normal cardiovascular system. Lewis and coworkers 28 noted arrhythmias in the course of 220 treatments of 21 patients anaesthetized most commonly with thiamylal and occasionally with thiopentone and pentobarbitone.
Results of our study indicate that in patients with a normal cardiovascular system, anaesthetized with methohexitone and relaxed with suxamethonium, preparation with atropine up to 1.0 mg intravenously confers no particular benefit or protection, nor does it result in adverse cardiovascular reactions not seen when atropine is administered. Whether these findings apply when other anaesthetics such as thiopentone or thiamylal are used has not been determined.
Apart from the anticholinergic effects of atropine on the cardiac vagus, it is frequently used in the preparation of surgical patients because of its antisialagogue properties. Our study shows that, at least in the case of electroconvulsive treatments, this property of atropine is unpredictable, is not dose-related and comparable results are frequently achieved without any drug at all. During the year since the conclusion of this study, atropine has not been used in our institution in connection with electroconvulsive therapy and the findings of this study have been fully confirmed in everyday clinical practice.
Atropine has recently been shown to relax the lower oesophageal sphincter, a somewhat unexpected finding,29.3o.31 and thus its omission may indeed be beneficial in the presence of the combination of succinylcholine and muscle contractions from the electrical shock.
